Novartis | NOVN - Selling And Administration Expenses


Novartis reported $3.24B in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Alcon AG USD 964M 82M Jun/2026
Amgen USD 1.72B 134M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Autolus Therapeutics Ltd USD 39.95M 4.16M Mar/2026
Bayer EUR 3.96B 267M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Fresenius EUR 760M 17M Jun/2026
Fresenius Medical Care EUR 736.01M 12.99M Jun/2026
Genmab DKK 205M 39M Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
GRIFOLS EUR 289M 8M Jun/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
J&J USD 6.42B 381M Jun/2026
Lakefront Biotherapeutics EUR 22.5M 13M Jun/2026
Merck EUR 1.57B 49M Jun/2026
Merck USD 2.89B 219M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Novartis USD 3.14B 296M Mar/2026
Novo Nordisk DKK 16.31B 3.09B Jun/2026
Orion EUR 98.9M 7M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Philips EUR 1.21B 23M Jun/2026
Recordati EUR 201.58M 8.82M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
UCB EUR 1.47B 193M Dec/2025